pulmonologyadvisor1d
Switching Biologics Occurs in 16% of Patients With Asthma, for Various Reasons
Patients with asthma who switched biologics multiple times were younger, more likely to identify as Black, and had more ...
The American Journal of Managed Care26d
Mepolizumab Reduces Exacerbations in Patients With Severe Asthma, Concurrent COPD, Posters Find
Mepolizumab significantly reduces exacerbations in patients with asthma and concurrent chronic obstructive pulmonary disease (COPD), with a 55% reduction in COPD exacerbations post initiation.
biopharma-reporter4d
AstraZeneca’s rare disease therapy Fasenra receives EU approval
The new treatment will be a competitor of GSK’s Nucala (mepolizumab), which was approved in 2018 as the first targeted ...
Pharmabiz5d
European Union approves AstraZeneca’s Fasenra for eosinophilic granulomatosis with polyangiitis
AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis ...
Daily2d
AstraZeneca Fasenra approved in the EU for eosinophilic granulomatosis with polyangiitis
Cambridge: AstraZeneca has announced that Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory ...